ContraFect presents positive data from Phase 2 trial of Exebacase
Category: #health  By Saif Ali Bepari  Date: 2019-04-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

ContraFect presents positive data from Phase 2 trial of Exebacase

The new data suggest the potential for exebacase to offer significant clinical assistance to patients with MRSA bloodstream infections.

U.S. clinical-stage biotechnology firm, ContraFect Corp. has recently announced new data from its Phase 2 clinical trial of exebacase for the treatment of Staphylococcus aureus bacteremia with endocarditis. The data was presented at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).

According to reliable reports, the data attained demonstrated clinically significant upsurge in clinical responder rates in the pre-determined MRSA (Methicillin Resistant Staphylococcus Aureus) subgroup subjected to exebacase, including a 22.9% higher responder rate at Day 7 and a 16.9% higher responder rate at TOC (Test of Cure), compared to MRSA patients subjected to SOC (standard of care) antibiotics alone.

Moreover, the pre-specified analyses of data from the overall population specified that patients with complex bacteremia had a 20.3% more responder rate with exebacase against those who were administered SOC alone.

Commenting on the attained results, Dr. Roger J. Pomerantz, President, CEO & Chairman, ContraFect said that the company is thrilled with the impressive results observed in the pre-specified MRSA subgroup subjected to exebacase.

He said that MRSA bloodstream infections continue to be an area of extremely high unmet clinical need with few treatment options, and their Phase 2 design study confirmed a clinical responder rate of 74.1% at Day 14 in the MRSA subpopulation, which signifies a 42.8% improvement over SOC antibiotics alone.

Pomerantz added that the firm is also pleased to speculate 20.3% more clinical responder rate at Day 14 among all complex bacteremia patients subjected to exebacase compared to those with SOC alone, further validating their belief that exebacase may play a key role in treating complicated bacteremia, as well as resistant infections such as MRSA.

Speaking on the achievement, Cara Cassino, M.D., CMD & Executive VP, Research & Development, ContraFect, said the firm is encouraged by these outcomes which strongly suggest the potential for exebacase to offer significant clinical benefit to patients with MRSA bloodstream infections. Moreover, the company is looking forward to expanding exebacase into a definitive Phase 3 trial, she said.

Source Credits: https://ir.contrafect.com/press-releases/detail/258/contrafect-presents-additional-positive-data-from-the-phase



About Author

Saif Ali Bepari

Email: [email protected]   

Saif Ali Bepari

Saif Ali Bepari currently works a content writer for Market Size Forecasters, Algosonline, and numerous other platforms. A Computer Science graduate who has a zest for writing over coding, he has previously dabbled into technical and creative writing. He now pens down...

Read More

More News By Saif Ali Bepari

Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
Altimmune inks deal to acquire Spitfire Pharma and its NASH candidate
By Saif Ali Bepari

Altimmune, Inc., a clinical stage biopharma company, has recently confirmed the closing of a formerly announced acquisition of Spitfire Pharma, Inc., including the strong GLP-1/Glucagon receptor co-agonist product cand...

NeurologyLive expands SAP program by partnering with Cleveland Clinic
NeurologyLive expands SAP program by partnering with Cleveland Clinic
By Saif Ali Bepari

NeurologyLive has reportedly added the Cleveland Clinic to its Strategic Alliance Partnership (SAP) program. Michael J. Hennessy Jr., President of NeurologyLive’s parent company MJH Associates Inc., said in a sta...

Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
Neurocrine, Voyager reveal VY-AADC’s Phase I results at AAN 2019
By Saif Ali Bepari

Neurocrine Biosciences Inc., along with Voyager Therapeutics Inc., has reportedly announced the Phase 1 results from the VY-AADC trial in eight patients suffering from Parkinson’s disease. Apparently, the patient...